ENTRY       D02933                      Drug
NAME        Anagrelide hydrochloride (USP);
            Agrylin (TN);
            Xagrid (TN)
FORMULA     C10H7Cl2N3O. HCl
EXACT_MASS  290.9733
MOL_WEIGHT  292.549
CLASS       Cardiovascular agent
             DG01507  Phosphodiesterase III inhibitor
            Metabolizing enzyme substrate
             DG01891  CYP1A1 substrate
             DG01892  CYP1A2 substrate
REMARK      ATC code: L01XX35
            Chemical structure group: DG00727
            Product (DG00727): D10255<JP/US>
EFFICACY    Thrombocythemia treatment, Platelet aggregation inhibitor, Phosphodiesterase inhibitor
TARGET      PDE3 [HSA:5139 5140] [KO:K19021 K13296]
  PATHWAY   hsa00230(5139+5140)  Purine metabolism
METABOLISM  Enzyme: CYP1A1 [HSA:1543], CYP1A2 [HSA:1544]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01X OTHER ANTINEOPLASTIC AGENTS
                L01XX Other antineoplastic agents
                 L01XX35 Anagrelide
                  D02933  Anagrelide hydrochloride (USP)
            Drug groups [BR:br08330]
             Cardiovascular agent
              DG01507  Phosphodiesterase III inhibitor
               DG00727  Anagrelide
                D02933  Anagrelide hydrochloride
             Metabolizing enzyme substrate
              DG01891  CYP1A1 substrate
               DG00727  Anagrelide
                D02933  Anagrelide hydrochloride
              DG01892  CYP1A2 substrate
               DG00727  Anagrelide
                D02933  Anagrelide hydrochloride
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Hydrolases (EC3)
               Phosphodiesterases
                PDE3
                 D02933  Anagrelide hydrochloride (USP)
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D02933
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D02933
            Drug groups [BR:br08330]
             Cardiovascular agent
              DG01507  Phosphodiesterase III inhibitor
               DG00727  Anagrelide
             Metabolizing enzyme substrate
              DG01891  CYP1A1 substrate
               DG00727  Anagrelide
              DG01892  CYP1A2 substrate
               DG00727  Anagrelide
DBLINKS     CAS: 58579-51-4
            PubChem: 17397090
            ChEBI: 55345
            LigandBox: D02933
            NIKKAJI: J244.913G
ATOM        17
            1   N1y N     9.8700   -6.3000
            2   C2y C     9.8700   -7.7000
            3   N2x N     8.6800   -8.4000
            4   C8y C     7.4200   -7.7000
            5   C8y C     7.4200   -6.3000
            6   C1x C     8.6100   -5.6000
            7   C8y C     6.2076   -5.6000
            8   C8y C     4.9951   -6.3000
            9   C8x C     4.9951   -7.7000
            10  C8x C     6.2076   -8.4000
            11  X   Cl    6.2076   -4.2000
            12  X   Cl    3.7827   -5.6000
            13  N1x N    11.2015   -8.1326
            14  C5x C    12.0244   -7.0000
            15  C1x C    11.2015   -5.8674
            16  O5x O    13.4244   -7.0000
            17  X   Cl   16.7300   -7.9800
BOND        18
            1     2   3 2
            2     3   4 1
            3     4   5 2
            4     5   6 1
            5     6   1 1
            6     1   2 1
            7     5   7 1
            8     7   8 2
            9     8   9 1
            10    9  10 2
            11   10   4 1
            12    7  11 1
            13    8  12 1
            14    2  13 1
            15   13  14 1
            16   14  15 1
            17    1  15 1
            18   14  16 2
///
